Last reviewed · How we verify
CCRT+GP
CCRT+GP combines concurrent chemoradiotherapy with gemcitabine and cisplatin followed by adjuvant chemotherapy to treat locally advanced cancers through combined cytotoxic and radiation effects.
CCRT+GP combines concurrent chemoradiotherapy with gemcitabine and cisplatin followed by adjuvant chemotherapy to treat locally advanced cancers through combined cytotoxic and radiation effects. Used for Locally advanced squamous cell carcinoma (head and neck or esophageal cancer).
At a glance
| Generic name | CCRT+GP |
|---|---|
| Also known as | Adjuvant GP |
| Sponsor | Sun Yat-sen University |
| Drug class | Combination chemotherapy and radiotherapy regimen |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This regimen integrates chemotherapy (gemcitabine and cisplatin) administered concurrently with radiotherapy to maximize local tumor control, followed by additional systemic chemotherapy cycles. The combination leverages radiosensitizing properties of the chemotherapy agents while delivering targeted radiation to the tumor bed, commonly used in head and neck or esophageal cancer protocols.
Approved indications
- Locally advanced squamous cell carcinoma (head and neck or esophageal cancer)
Common side effects
- Mucositis
- Hematologic toxicity (anemia, leukopenia, thrombocytopenia)
- Nausea and vomiting
- Dysphagia
- Dermatitis
Key clinical trials
- Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma (PHASE2)
- Neoadjuvant Therapy of GP Chemotherapy Combined With Tislelizumab in Locoregionally Advanced NPC (PHASE2)
- GP Combined with Toripalimab Versus GP Induction Chemotherapy for Advanced Childhood Nasopharyngeal Carcinoma (PHASE2)
- Toripalimab Vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma (PHASE3)
- GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma (PHASE3)
- Penpulimab Combined With GP ± Anlotinib as Neoadjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma (PHASE2)
- TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma (PHASE2)
- GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CCRT+GP CI brief — competitive landscape report
- CCRT+GP updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI